Enfortumab Vedotin-ejfv
Padcev is an antibody-drug conjugate designed to treat adults with locally advanced or metastatic urothelial cancer (the most common type of bladder cancer) who have previously received a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. It delivers a targeted chemotherapy agent directly to cancer cells expressing Nectin-4, a protein commonly found on urothelial cancer cells.
Padcev is a targeted therapy for advanced bladder cancer that delivers chemotherapy directly to cancer cells in patients who have failed prior treatments.
Key facts at a glance
- RxNorm
- 2268093
- Generic
- Padcev
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Padcev is indicated for the treatment of adults with locally advanced or metastatic urothelial cancer (bladder cancer, ureter cancer, or cancer of the renal pelvis) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy regimen.
Padcev is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody that binds to Nectin-4, a cell adhesion protein that is highly expressed on urothelial cancer cells. Once bound, the conjugate is internalized and releases the cytotoxic agent monomethyl auristatin E (MMAE), which disrupts the microtubule network within the cancer cell, leading to cell death.
Padcev may cause serious side effects including skin reactions, hyperglycemia, peripheral neuropathy, ocular disorders, and infusion site extravasation. It is contraindicated in patients with known severe hypersensitivity to the drug. Treatment should be administered by healthcare professionals experienced in the use of anticancer agents. Pregnant women should not receive Padcev due to potential harm to the fetus.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy